Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective
Chiara Brullo, Carla Villa, Bruno Tasso, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 14, pp. 7641-7641
Open Access | Times Cited: 47

Showing 1-25 of 47 citing articles:

Bruton tyrosine kinase inhibitors for multiple sclerosis
Julia Krämer, Amit Bar‐Or, Timothy J. Turner, et al.
Nature Reviews Neurology (2023) Vol. 19, Iss. 5, pp. 289-304
Open Access | Times Cited: 98
In situ identification of cellular drug targets in mammalian tissue
Zhengyuan Pang, Michael A. Schafroth, Daisuke Ogasawara, et al.
Cell (2022) Vol. 185, Iss. 10, pp. 1793-1805.e17
Open Access | Times Cited: 51
The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions
Tadeusz Robak, Magdalena Witkowska, Piotr Smolewski
Cancers (2022) Vol. 14, Iss. 3, pp. 771-771
Open Access | Times Cited: 47
Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives
Ewa Robak, Tadeusz Robak
Journal of Clinical Medicine (2022) Vol. 11, Iss. 10, pp. 2807-2807
Open Access | Times Cited: 47
From development to clinical success: the journey of established and next-generation BTK inhibitors
Shivani Gupta, Arpit Sharma, Alok Kumar Shukla, et al.
Investigational New Drugs (2025)
Closed Access | Times Cited: 1
The Development of BTK Inhibitors: A Five-Year Update
Bruno Tasso, Andrea Spallarossa, Eleonora Russo, et al.
Molecules (2021) Vol. 26, Iss. 23, pp. 7411-7411
Open Access | Times Cited: 50
Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases
Datong Zhang, Gong He, Fancui Meng
Molecules (2021) Vol. 26, Iss. 16, pp. 4907-4907
Open Access | Times Cited: 49
Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?
Anastasia Geladaris, Sebastian Torke, Martin S. Weber
CNS Drugs (2022) Vol. 36, Iss. 10, pp. 1019-1030
Open Access | Times Cited: 30
Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL)
Alexandra Chirino, Skye Montoya, Anita Safronenka, et al.
Genes (2023) Vol. 14, Iss. 12, pp. 2182-2182
Open Access | Times Cited: 19
COVID-19 in patients with anemia and haematological malignancies: risk factors, clinical guidelines, and emerging therapeutic approaches
Sareh Kakavandi, Bahareh Hajikhani, Paniz Azizi, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 7
Recent development of BTK-based dual inhibitors in the treatment of cancers
Fansheng Ran, Yun Liu, Zhongyuan Xu, et al.
European Journal of Medicinal Chemistry (2022) Vol. 233, pp. 114232-114232
Closed Access | Times Cited: 21
Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib
David Yin-wei Lin, Amy H. Andreotti
PLoS ONE (2023) Vol. 18, Iss. 8, pp. e0290872-e0290872
Open Access | Times Cited: 12
B cell activation and autoantibody production in autoimmune diseases
Wenbo Sun, Can Zhu, Yuxin Li, et al.
Best Practice & Research Clinical Rheumatology (2024) Vol. 38, Iss. 2, pp. 101936-101936
Closed Access | Times Cited: 3
Bruton tyrosine kinase inhibitors in multiple sclerosis: evidence and expectations
Julia Krämer, Heinz Wiendl
Current Opinion in Neurology (2024) Vol. 37, Iss. 3, pp. 237-244
Closed Access | Times Cited: 3
A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis
Nicolas Collongues, Guillaume Becker, Valérie Jolivel, et al.
Neurology and Therapy (2022) Vol. 11, Iss. 3, pp. 981-1042
Open Access | Times Cited: 13
Advanced approaches of developing targeted covalent drugs
Conghao Gai, Suzannah J. Harnor, Shihao Zhang, et al.
RSC Medicinal Chemistry (2022) Vol. 13, Iss. 12, pp. 1460-1475
Open Access | Times Cited: 13
Controlling Ibrutinib’s Conformations about Its Heterobiaryl Axis to Increase BTK Selectivity
Sean T. Toenjes, Bahar S. Heydari, Samuel T. Albright, et al.
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 3, pp. 305-311
Open Access | Times Cited: 7
Investigation of VEGF (rs 699947) polymorphism in the progression of Rheumatoid Arthritis (RA) and in-silico nanoparticle drug delivery of potential phytochemicals to cure RA
Nageen Hussain, Mohsin Mumtaz, Mohammad Adil, et al.
Acta Biochimica Polonica (2023)
Open Access | Times Cited: 7
Next-generation Bruton’s Tyrosine Kinase (BTK) Inhibitors Potentially Targeting BTK C481S Mutation- Recent Developments and Perspectives
Debasis Das, Jingbing Wang, Jian Hong
Current Topics in Medicinal Chemistry (2022) Vol. 22, Iss. 20, pp. 1674-1691
Closed Access | Times Cited: 11
Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia
Anna Wolska, Tadeusz Robak
Expert Review of Hematology (2022) Vol. 15, Iss. 3, pp. 183-194
Closed Access | Times Cited: 10
Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis
Edgar Carnero Contentti, Jorge Correale
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 3473-3490
Open Access | Times Cited: 10
New small molecules in dermatology: for the autoimmunity, inflammation and beyond
Paulo Ricardo Criado, Daniel Lorenzini, Hélio Amante Miot, et al.
Inflammation Research (2023) Vol. 72, Iss. 6, pp. 1257-1274
Open Access | Times Cited: 5
Quantification of orelabrutinib in human plasma and cerebrospinal fluid by liquid chromatography tandem mass spectrometry
Shengnan Ji, Xiaomeng Liu, Jing Ha, et al.
Journal of Chromatography B (2023) Vol. 1221, pp. 123680-123680
Closed Access | Times Cited: 4
Integrating machine learning algorithms and single-cell analysis to identify gut microbiota-related macrophage biomarkers in atherosclerotic plaques
Yin Ke, Yue Jian, Jiaming He, et al.
Frontiers in Cellular and Infection Microbiology (2024) Vol. 14
Open Access | Times Cited: 1
Conjugate of ibrutinib with a TLR7 agonist suppresses melanoma progression and enhances antitumor immunity
Sumei Ren, Xiaodong Wang, Guangyi Jin
International Journal of Biological Sciences (2021) Vol. 18, Iss. 1, pp. 166-179
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top